| Assessment of second-line antiretroviral regimens for HIV therapy in Africa NI Paton, C Kityo, A Hoppe, A Reid, A Kambugu, A Lugemwa, ... New England journal of medicine 371 (3), 234-247, 2014 | 240 | 2014 |
| Oxidative stress in obstructive nephropathy A Dendooven, DA Ishola Jr, TQ Nguyen, DM Van der Giezen, RJ Kok, ... International journal of experimental pathology 92 (3), 202-210, 2011 | 155 | 2011 |
| Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology CR Beck, BC McKenzie, AB Hashim, RC Harris, ... The Journal of infectious diseases 206 (8), 1250-1259, 2012 | 146 | 2012 |
| In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent DA Ishola Jr, DM van der Giezen, B Hahnel, R Goldschmeding, W Kriz, ... Nephrology Dialysis Transplantation 21 (3), 591-597, 2006 | 98 | 2006 |
| Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within … NI Paton, C Kityo, J Thompson, I Nankya, L Bagenda, A Hoppe, J Hakim, ... The lancet HIV 4 (8), e341-e348, 2017 | 82 | 2017 |
| Prevention of Ebola virus disease through vaccination: where we are in 2018 Y Lévy, C Lane, P Piot, AH Beavogui, M Kieh, B Leigh, S Doumbia, ... The Lancet 392 (10149), 787-790, 2018 | 80 | 2018 |
| Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco … AQ Adigun, DA Ishola, AO Akintomide, AAL Ajayi Journal of human hypertension 17 (4), 277-285, 2003 | 78 | 2003 |
| Albumin-bound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximal tubular cells DA Ishola Jr, JA Post, MM van Timmeren, SJL Bakker, R Goldschmeding, ... Kidney international 70 (4), 724-731, 2006 | 76 | 2006 |
| Safety and long-term immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: A combined open-label, non … D Ishola, D Manno, MO Afolabi, B Keshinro, V Bockstal, B Rogers, ... The Lancet Infectious Diseases 22 (1), 97-109, 2022 | 75 | 2022 |
| Midwives' influenza vaccine uptake and their views on vaccination of pregnant women DA Ishola Jr, N Permalloo, RJ Cordery, SR Anderson Journal of Public Health 35 (4), 570-577, 2013 | 72 | 2013 |
| Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective CR Beck, BC McKenzie, AB Hashim, RC Harris, A Zanuzdana, ... PloS one 6 (12), e29249, 2011 | 68 | 2011 |
| Safety and immunogenicity of the two-dose heterologous Ad26. ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial MO Afolabi, D Ishola, D Manno, B Keshinro, V Bockstal, B Rogers, ... The Lancet Infectious Diseases 22 (1), 110-122, 2022 | 67 | 2022 |
| Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction DA Ishola Jr, R Borrow, H Findlow, J Findlow, C Trotter, ME Ramsay Clinical and vaccine immunology 19 (8), 1126-1130, 2012 | 67 | 2012 |
| Could influenza transmission be reduced by restricting mass gatherings? Towards an evidence-based policy framework DA Ishola, N Phin Journal of epidemiology and global health 1 (1), 33-60, 2011 | 65 | 2011 |
| Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT2 receptor S Wesseling, DA Ishola Jr, JA Joles, HA Bluyssen, HA Koomans, B Braam American Journal of Physiology-Renal Physiology 288 (6), F1191-F1200, 2005 | 53 | 2005 |
| “We are the heroes because we are ready to die for this country”: Participants' decision-making and grounded ethics in an Ebola vaccine clinical trial AF Tengbeh, L Enria, E Smout, T Mooney, M Callaghan, D Ishola, B Leigh, ... Social science & medicine 203, 35-42, 2018 | 52 | 2018 |
| Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up … JG Hakim, J Thompson, C Kityo, A Hoppe, A Kambugu, JJ van Oosterhout, ... The Lancet Infectious Diseases 18 (1), 47-57, 2018 | 52 | 2018 |
| The evolutionary dynamics of influenza A virus adaptation to mammalian hosts S Bhatt, TT Lam, SJ Lycett, AJ Leigh Brown, TA Bowden, EC Holmes, ... Philosophical Transactions of the Royal Society B: Biological Sciences 368 …, 2013 | 50 | 2013 |
| EBOVAC-Salone: lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country T Mooney, E Smout, B Leigh, B Greenwood, L Enria, D Ishola, D Manno, ... Clinical Trials 15 (5), 436-443, 2018 | 41 | 2018 |
| Influenza vaccination for immunocompromised patients: summary of a systematic review and meta‐analysis CR Beck, BC McKenzie, AB Hashim, RC Harris, A Zanuzdana, ... Influenza and other respiratory viruses 7, 72-75, 2013 | 40 | 2013 |
